Brief: Orion Says Phase III Aranote Trial Of Darolutamide Meets Primary Endpoint
17/07/2024 06:32
July 17 (Reuters) - Orion Oyj ORNBV.HE :
* REG-INSIDE INFORMATION: PHASE III ARANOTE TRIAL OF
DAROLUTAMIDE
IN COMBINATION WITH ANDROGEN DEPRIVATION THERAPY IN MEN WITH
METASTATIC HORMONE-SENSITIVE PROSTATE CANCER MEETS PRIMARY
ENDPOINT
* ORION AND BAYER'S PHASE III ARANOTE TRIAL MEETS PRIMARY
ENDPOINT, SIGNIFICANTLY INCREASING RADIOLOGICAL PROGRESSION-FREE
SURVIVAL (RPFS) WITH DAROLUTAMIDE + ANDROGEN DEPRIVATION THERAPY
(ADT) COMPARED TO PLACEBO PLUS ADT
* SAFETY ANALYSIS SHOWS DAROLUTAMIDE PLUS ADT TO BE
COMPARABLE TO
PLACEBO PLUS ADT, RECONFIRMING ESTABLISHED TOLERABILITY PROFILE
OF DAROLUTAMIDE AS OBSERVED IN ARAMIS AND ARASENS TRIALS
* DAROLUTAMIDE PLUS ADT NOW HAS POSITIVE DATA BOTH WITH AND
WITHOUT DOCETAXEL BASED ON TWO PIVOTAL PHASE III STUDIES IN
METASTATIC HORMONE-SENSITIVE PROSTATE CANCER (MHSPC)
Source text for Eikon: ID:nGNE5Y7YDB
Further company coverage: ORNBV.HE
(Gdansk Newsroom)
((gdansk.newsroom@thomsonreuters.com; +48 58 772 0920;))